BRAF and melanoma: In pivotal, global phase 3 studies, the combination of dabrafenib and trametinib demonstrated statistically significant and clinically relevant improvements in progression-free survival (PFS) and overall survival in patients with BRAF V600 mutation–positive melanoma, which established this combination therapy as a standard treatment option for BRAF V600 mutation–positive melanoma [12].